Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma

Radiotherapy for Esthesioneuroblastoma: Is Elective Nodal Irradiation Warranted in the Multimodality Treatment Approach?

“…Definitive radiotherapy with or without chemotherapy is also frequently used in patients with locally advanced, unresectable tumors, suggesting that concurrent chemoradiotherapy may be an alternative Abbreviations: RT = radiotherapy; CRT = chemoradiotherapy; ENI = elective nodal irradiation. primary modality in patients with advanced-stage ENB (13). In this study radiotherapy was used as a definitive or adjuvant treatment in most patients, resulting in an overall survival rate comparable to data from previous studies (4,14,15).…”

Outcome and Prognostic Factors in Olfactory Neuroblastoma: A Rare Cancer Network Study

“…The current accepted practice is open or endoscopic craniofacial surgical resection (7,8,11,13,16). Adjuvant RT is indicated for Kadish Stage B and C (7)(8)(9)(10)(11)(12), whereas Kadish A disease can be managed by surgery alone (20). In our series, combined surgery and postoperative RT gave the best outcome, particularly when the total RT dose was $54 Gy.…”

“…Using combined modality treatment, many series report good locoregional control (6,7,10,11); however, when negative surgical margins are obtained, adjuvant radiation therapy (RT) remains questionable according to some authors (12,13). The role of chemotherapy in the treatment of ONB is controversial, both postoperatively and before resection (14)(15)(16)(17)(18)(19)(20).…”

Long‐term results of 28 esthesioneuroblastomas managed over 35 years

“…11,15,47,48 Recently, several series have focused on concurrent chemoradiotherapy as initial treatment modality in advanced olfactory neuroblastoma. 49,50 They suggest the feasibility of nonsurgical treatment, although the number of treated patients is small and the follow-up is too short. However, until now, our experience has been without chemotherapy, our follow-up is long, and the 88.6% disease-specific survival rate at 5 and 15 years does not plead for its use.…”